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background: Stent thrombosis (ST) is an infrequent event following 2nd generation drug-eluting stents (DES); however, its occurrence may be 
catastrophic. Our objective was to report the incidence of ST in a large population treated with Endeavor zotarolimus-eluting stents (E-ZES) and 
randomized to short- (3 months) versus long-term (12 months) dual antiplatelet therapy (DAPT).
methods: The OPTIMIZE trial was a randomized (1:1), active-controlled, open-label study including 3,119 patients in 33 sites in Brazil between 
April/2010-March/2012. Clinical follow-up was performed at 1, 3, 6 and 12 months. ST (secondary endpoint) was defined according to the 
Academic Research Consortium (ARC).
results: Baseline characteristics of pts allocated in the short- (n=1,563) vs. long-term (n=1,556) groups were well-balanced, including mean age 
(61.3 vs 61.9 yrs), diabetes (35.4% vs 35.3%), current smoking (18.6% vs 17.3%), renal insufficiency (7.4% vs 5.8%), previous MI (34.6% vs 34.8%), 
and clinical presentation of recent acute coronary syndrome (31.6% vs 32.3%). Lesion characteristics were also similar, including bifurcations 
(14.7% vs 14.9%) and lesion type C (37% vs 37.4%), respectively. Multivessel PCI was performed in 26% of cases, there were 1.6±0.8 stents 
implanted per patient, and nominal stent length was 32.75 vs 32.72 mm. Overall, there were 25 cases of def./prob. ST (ARC) occurring up to 1 year 
(0.8%), and the incidence of early (0-30 days) and late (31-360 days) events comparing short- and long-term groups were 0.4% vs. 0.5% (p=0.59), 
and 0.5% versus 0.3% (p=0.37), respectively. ST up to 90 days occurred in 9 pts in the short-term group (0.6%) and in 11 pts in the long-term group 
(0.7%) (Hazard Ratio [HR] 0.81; 95% CI 0.34-1.96); from 91 to 360 days, event-rates were 0.3% (4 cases) and 0.1% (1 case) for short- versus long-
term groups, respectively (HR 3.97; 95% CI 0.44-35.49).
Conclusions: In the OPTIMIZE trial, the overall ARC definite/probable ST rate was low and not significantly associated with DAPT duration. Still, 
given the very low number of events, this analysis might had not been able to demonstrate any trends favoring one of the groups.
